SFM
ACAD icon

Sphera Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Sphera Funds Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$1.85M – 119
2024
Q1 		$1.85M Buy
+100,000
New +$2.48M 0.26% 80

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Sphera Funds Management's ACAD Position: Q1 2026 in Review

Sphera Funds Management increased its Acadia Pharmaceuticals (ACAD) stake by 21% in Q1 2026, buying an estimated $1.05M and bringing the position to 256,202 shares worth $5.7M. The position accounts for 0.91% of the portfolio, ranked #40.

Sphera Funds Management first reported a position in ACAD in Q4 2013 and has held it in 16 quarters since. The position peaked at $15.3M in Q4 2019. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Sphera Funds Management held 256,202 shares of Acadia Pharmaceuticals worth $5.7M as of Q1 2026.
  • Sphera Funds Management bought 44,000 Acadia Pharmaceuticals shares in Q1 2026, an estimated $1.05M.
  • Acadia Pharmaceuticals made up 0.91% of Sphera Funds Management's portfolio in Q1 2026, its #40 holding.
  • Sphera Funds Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 16 quarters since.
  • Sphera Funds Management's Acadia Pharmaceuticals position peaked at $15.3M in Q4 2019.
  • 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.